Containment DNA Packaging Trials 
Drug Discovery World
DECEMBER 15, 2022
These platforms all induce double strand cuts in the chromosomal DNA that can be sealed by the cell, leading to a specific gene disruption, or resulting in a new target site for inserting DNA segments. Early phase clinical trials for gene editing therapies. Gene editing challenges and potential solutions.
The Pharma Data
AUGUST 3, 2021
Food and Drug Administration (FDA) has determined that OAV-101 intrathecal (IT) clinical trials for spinal muscular atrophy (SMA) patients may proceed, thereby lifting the partial clinical trial hold initiated in October 2019. Novartis today announced that the U.S. SVP, Chief Medical Officer, Novartis Gene Therapies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MARCH 27, 2023
The UK government endorses TREs, having recently announced an investment package of up to £200 million in TREs and digitally enabled clinical trials 4. A robust environment will contain secure access controls that can prevent and detect misuse of data.
Pfizer
DECEMBER 13, 2022
In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. For more information, please visit www.PAXLOVID.com.
Pfizer
DECEMBER 20, 2022
Results from these analyses are consistent with previously disclosed efficacy and safety data for the trials. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. The information contained in this statement is as of December 20, 2022. Disclosure Notice.
Pfizer
JANUARY 27, 2023
In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course.
The Pharma Data
SEPTEMBER 1, 2020
COVID-19 testing solutions that provide healthcare professionals and patients with a quick answer regarding their infection status are critical to contain the community-spread of the COVID-19 virus. Roche has an ongoing clinical trial program evaluating the role of Actemra©/RoActemra© (tocilizumab) in COVID-19 pneumonia.
Expert insights. Personalized for you.
52 
Let's personalize your content